PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. EXPERIMENTAL DESIGN: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. RESULTS: Forty-six tumors (72%) in our cohort had 1p/19q loss and 18 (28%) had 1p/19q maintenance. Of those with loss, 19 (41%) had concurrent polysomy and 27 (59%) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and overall survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. CONCLUSION: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.
PURPOSE: Loss of chromosome arms 1p and 19q is a molecular feature of oligodendroglial tumors characterized by responsiveness to chemotherapy and a favorable prognosis. The purpose of this study was to evaluate the prognostic significance of polysomy of chromosomes 1 and 19 in the setting of 1p/19q codeletion. EXPERIMENTAL DESIGN: We analyzed 64 anaplastic oligodendrogliomas with 1p/19q loss or maintenance diagnosed at Massachusetts General Hospital and Brigham and Women's Hospital from 1996 to 2005; fluorescence in situ hybridization for 1p/19q and Ki-67 immunohistochemistry was done. Polysomy was defined as more than two 1q and 19p signals in >30% of the cells with concurrent 1p/19q deletion. Tumors were divided into groups based on their 1p/19q status and compared for progression-free survival, overall survival, and 5-year survival probabilities. RESULTS: Forty-six tumors (72%) in our cohort had 1p/19q loss and 18 (28%) had 1p/19q maintenance. Of those with loss, 19 (41%) had concurrent polysomy and 27 (59%) lacked polysomy. In agreement with previous studies, the group of anaplastic oligodendrogliomas with 1p/19q loss had significantly better progression-free survival and overall survival than anaplastic oligodendrogliomas with 1p/19q maintenance (P = 0.0009 and P < 0.0003, respectively). Among anaplastic oligodendrogliomas with 1p/19q loss, those with polysomy showed shorter progression-free survival than those with 1p/19q loss without polysomy (P = 0.0048). Overall survival was similar in tumors with and without polysomy. The Ki-67 labeling index was not associated with polysomy and did not have prognostic significance. CONCLUSION: The presence of polysomy in anaplastic oligodendrogliomas with deletion of 1p/19q is a marker of earlier recurrence.
Authors: G S Bauman; Y Ino; K Ueki; M C Zlatescu; B J Fisher; D R Macdonald; L Stitt; D N Louis; J G Cairncross Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: J S Smith; I Tachibana; U Pohl; H K Lee; U Thanarajasingam; B P Portier; K Ueki; S Ramaswamy; S J Billings; H W Mohrenweiser; D N Louis; R B Jenkins Journal: Genomics Date: 2000-02-15 Impact factor: 5.736
Authors: Y Ino; R A Betensky; M C Zlatescu; H Sasaki; D R Macdonald; A O Stemmer-Rachamimov; D A Ramsay; J G Cairncross; D N Louis Journal: Clin Cancer Res Date: 2001-04 Impact factor: 12.531
Authors: M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross Journal: Cancer Res Date: 2001-09-15 Impact factor: 12.701
Authors: J S Smith; I Tachibana; H K Lee; J Qian; U Pohl; H W Mohrenweiser; T J Borell; S M Hosek; C L Soderberg; A von Deimling; A Perry; B W Scheithauer; D N Louis; R B Jenkins Journal: Genes Chromosomes Cancer Date: 2000-09 Impact factor: 5.006
Authors: Martin J van den Bent; Leendert H J Looijenga; K Langenberg; Winand Dinjens; Wilfried Graveland; Ludo Uytdewilligen; Peter A Sillevis Smitt; Robert B Jenkins; Johan M Kros Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: Christian Hartmann; Loki Johnk; Gaspar Kitange; Yanhong Wu; Linda K Ashworth; Robert B Jenkins; David N Louis Journal: Cancer Res Date: 2002-07-15 Impact factor: 12.701
Authors: Chih-Chun Wu; Rajan Jain; Lucidio Neto; Seema Patel; Laila M Poisson; Jonathan Serrano; Victor Ng; Sohil H Patel; Dimitris G Placantonakis; David Zagzag; John Golfinos; Andrew S Chi; Matija Snuderl Journal: Neuroradiology Date: 2019-05-27 Impact factor: 2.804